SARC025 / ESP1

SARC025/ESP1 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma

TYPE OF SARCOMA: Ewing Sarcoma
DRUG: Niraparib, Temozolomide and Irinotecan

ACCRUAL STATUS: Completed

OVERALL STUDY PRINCIPAL INVESTIGATORS:
Rashmi Chugh, MD
University of Michigan

Sandra Strauss, MBBS, PhD
University College London, Cancer Institute

CLINICALTRIALS.GOV IDENTIFIER: NCT02044120

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

PUBLICATION:
Chugh R, Ballman KV, Helman LJ, Patel S, Whelan JS, Widemann B, Lu Y, Hawkins DS, Mascarenhas L, Glod JW, Ji J, Zhang Y, Reinke D, Strauss SJ. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer. 2021 Apr 15;127(8):1301-1310. doi: 10.1002/cncr.33349. Epub 2020 Dec 8. PMID: 33289920; PMCID: PMC8246769.

To learn more about this study or to contact the study research staff: